The Department of Health and Human Services recently released its budget proposal for 2010. As it relates to the FDA, HHS is looking to build
on the $1.1billion included in the recovery Act for comparative effectiveness research. The funds requested will continue efforts to produce state-of-the-science information on what medical treatments work best for a given condition.
Not only will these findings enhance medical decision-making by patients and their physicians, they will likely close the door a little bit more to the success of off-label marketing of pharmaceuticals for indications that have little to no science to back up the claims of efficacy. Physicians will hopefully have a readily available source from which to compare treatments and drugs.